NO20051852L - Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer. - Google Patents

Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.

Info

Publication number
NO20051852L
NO20051852L NO20051852A NO20051852A NO20051852L NO 20051852 L NO20051852 L NO 20051852L NO 20051852 A NO20051852 A NO 20051852A NO 20051852 A NO20051852 A NO 20051852A NO 20051852 L NO20051852 L NO 20051852L
Authority
NO
Norway
Prior art keywords
compounds
tgf
growth factor
transforming growth
inhibitors
Prior art date
Application number
NO20051852A
Other languages
English (en)
Inventor
Michael John Munchhof
Laura Cook Blumberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051852L publication Critical patent/NO20051852L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

2005 ~06- 6 Det beskrives nye isotiazol- og isoksazol forbindelser inkludert derivater derav. Videre beskrives det mellomprodukter for fremstilling av forbindelsene, farmasøytiske preparater inneholdende forbindelsene og disses medisinske anvendelse. Forbindelsene i følge oppfinnelsen er potente inhibitorer av den transformerende vekstfaktor ("TGF")-P signalvei. Forbindelsene finner anvendelse ved behandling av forskjellige TGF-relaterte sykdomstilstander inkludert for eksempel canser og fibrotiske sykdommer.
NO20051852A 2002-09-18 2005-04-15 Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer. NO20051852L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41213102P 2002-09-18 2002-09-18
US48458003P 2003-07-02 2003-07-02
PCT/IB2003/004005 WO2004026865A1 (en) 2002-09-18 2003-09-12 Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
NO20051852L true NO20051852L (no) 2005-06-16

Family

ID=32033584

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051852A NO20051852L (no) 2002-09-18 2005-04-15 Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.

Country Status (25)

Country Link
US (1) US7030125B2 (no)
EP (1) EP1542995A1 (no)
JP (1) JP2006506443A (no)
KR (1) KR20050057441A (no)
CN (1) CN1681809A (no)
AP (1) AP2005003262A0 (no)
AR (1) AR041275A1 (no)
AU (1) AU2003263431A1 (no)
BR (1) BR0314286A (no)
CA (1) CA2499332A1 (no)
CO (1) CO5550458A2 (no)
EA (1) EA200500286A1 (no)
EC (1) ECSP055685A (no)
HR (1) HRP20050246A2 (no)
IS (1) IS7695A (no)
MA (1) MA27444A1 (no)
MX (1) MXPA05002378A (no)
NO (1) NO20051852L (no)
OA (1) OA12925A (no)
PA (1) PA8583101A1 (no)
PE (1) PE20050076A1 (no)
PL (1) PL375973A1 (no)
TW (1) TW200410954A (no)
UY (1) UY27983A1 (no)
WO (1) WO2004026865A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
HRP20050247A2 (en) * 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
JP4547271B2 (ja) * 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
NZ560712A (en) * 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
LT2970890T (lt) 2013-03-14 2020-07-10 The Brigham And Women`S Hospital, Inc. Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5095272A (no) * 1973-12-24 1975-07-29
EP0983260A2 (en) 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
WO2002062787A1 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2004013135A1 (en) 2002-07-31 2004-02-12 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors

Also Published As

Publication number Publication date
EA200500286A1 (ru) 2005-08-25
PE20050076A1 (es) 2005-03-26
UY27983A1 (es) 2004-04-30
CA2499332A1 (en) 2004-04-01
US7030125B2 (en) 2006-04-18
ECSP055685A (es) 2005-05-30
EP1542995A1 (en) 2005-06-22
US20040116473A1 (en) 2004-06-17
WO2004026865A1 (en) 2004-04-01
PA8583101A1 (es) 2004-04-23
IS7695A (is) 2005-02-14
AP2005003262A0 (en) 2005-03-31
BR0314286A (pt) 2005-08-02
KR20050057441A (ko) 2005-06-16
HRP20050246A2 (en) 2005-10-31
TW200410954A (en) 2004-07-01
MA27444A1 (fr) 2005-07-01
JP2006506443A (ja) 2006-02-23
CO5550458A2 (es) 2005-08-31
PL375973A1 (en) 2005-12-12
AU2003263431A1 (en) 2004-04-08
MXPA05002378A (es) 2005-05-23
CN1681809A (zh) 2005-10-12
OA12925A (en) 2006-10-13
AR041275A1 (es) 2005-05-11

Similar Documents

Publication Publication Date Title
NO20051852L (no) Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
SE9903760D0 (sv) New compounds
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
HUP0402560A2 (hu) N-(Adamantil-metil)-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
BRPI0407055A (pt) Derivados de isotiazol
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
DE60229287D1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
HUP0300191A2 (hu) 2,6-Diamino-6-metil-heptánsav és származékai, eljárás ezek előállítására és alkalmazásuk
EP1802297A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES INDIRECTED BY INFECTION WITH YERSINIA SPP
AR022044A1 (es) Derivados de 1,5-benzodiazepina